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Abstract
Drugs in the same class are generally thought to be therapeutically equivalent because of similar
mechanisms of action (the so-called "class effect"). However, statins differ in multiple
characteristics, including liver and renal metabolism, half-life, effects on several serum lipid
components, bioavailability and potency. Some are fungal derivatives, and others are synthetic
compounds. The percentage absorption of an oral dose, amount of protein binding, degree of renal
excretion, hydrophilicity, and potency on a weight basis is variable. These differences may be even
greater in diabetic patients, who may present diabetes-induced abnormalities in P450 isoforms and
altered hepatic metabolic pathways. Thus, it is obvious that head-to-head comparisons between
different statins are preferable than trial-to-trial comparisons. Such assessments are of utmost
importance, especially in cases in which specific populations with a distinct lipid profile and altered
metabolic pathways, like diabetics, are studied. It should be specially pinpointed that patients with
metabolic syndrome and diabetes constitute also a special population regarding their atherogenic
dyslipidemia, which is usually associated with low HDL-cholesterol, hypertriglyceridemia and
predominance of small dense LDL-cholesterol. Therefore, these patients may benefit from fibrates
or combined statin/fibrate treatment. This policy is not accomplished since in the real world things
are more complex. Trials would require very large sample sizes and long-term follow-up to detect
significant differences in myocardial infarction or death between two different statins. Moreover,
the fact that new compounds are under several phases of research and development represents an
additional drawback for performing the trials. Ideally, head-to-head trials regarding clinically
important outcomes should be conducted for all drugs. Nonetheless, the desirability of performing
such trials, which epitomize modern evidence-based medicine, is frequently superseded by the
feasibility dictated by pragmatic and economic circumstances. In the latter case, in absence of solid
systematic documentation of comparable health benefits and long-term safety, both researchers
and practicing physicians should allude to the weight of scientific endorsement behind the
arguments and seek for the possible strengths and weaknesses intrinsic to each specific study. In
any case, conclusions based on surrogate endpoints cannot completely substitute head-to-head
comparisons regarding patients' outcome.
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During the last fifteen years large-scale clinical trials were
conducted aiming to determine the antihyperlipidemic
activity of several 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins). These studies included the
Scandinavian Simvastatin Survival Study (4S) [1], the
West of Scotland Coronary Prevention Study
(WOSCOPS) [2], the Expanded Clinical Evaluation of
Lovastatin (EXCEL) study [3], among others. Several
important concepts emerged from these studies. It was
shown that lipid-lowering pharmacotherapy is justified
for patients with hypercholesterolemia who are at risk of
coronary artery disease (CAD). Lipid-lowering medication
produced significant reductions in death from CAD and
non-fatal myocardial infarction (MI), all cardiovascular
death and all-cause mortality, clearly supporting the use
of statins in such patients. In addition, statins induced
modest increases in high-density lipoprotein cholesterol,
and decreases in triglycerides [1-3]. No direct compari-
sons between these drugs were available at this stage.
Thus, questions regarding the relative superiority and/or
safety of a given compound remained unanswered. These
queries have need of an appropriate response.
Head-to-head comparisons
Following the pioneering initial studies, more recent
head-to-head comparative parallel-group trials unveiled
additional features of this type of drugs. In 2001, the
Reversal of Atherosclerosis with Aggressive Lipid Lowering
(REVERSAL) trial demonstrated that atorvastatin 80 mg/
day partially reversed carotid intima-media thickness in
patients with familial hypercholesterolemia, as compared
with simvastatin 40 mg/day [4].
Furthermore, the Atorvastatin versus Simvastatin on
Atherosclerosis Progression (ASAP) trial study showed
that high-dose atorvastatin delayed progression of coro-
nary atherosclerosis, as assessed by intravascular ultra-
sound, while 40 mg/day pravastatin did not [5]. These
trials demonstrated that aggressive statin therapy is more
effective in terms of atherosclerosis progression. Impor-
tantly, statins have also demonstrated to reduce endothe-
lial dysfunction, inflammation, noxious cytokines
concentration and blood thrombogenicity, which all
seem to be co-responsible for plaque thrombosis [6,7].
In the Pravastatin or Atorvastatin Evaluation and Infec-
tion Therapy (PROVE-IT) trial [8] 4162 patients who had
suffered an acute coronary syndrome in the preceding 10
days were randomized to receive pravastatin 40 mg/day vs
atorvastatin 80 mg/day in addition to gatifloxacin vs pla-
cebo. The data of the lipid-lowering therapy showed mean
low-density lipoprotein (LDL) levels of 95 mg/dl in the
pravastatin group, in compliance with present guidelines
of clinical practice, and 62 mg/dl in the atorvastatin
group. After a follow-up of 2 years, the intensive lipid-
lowering group showed a significant reduction in the inci-
dence of the combined end-point of death, MI, unstable
angina requiring hospitalization, revascularization and
stroke. The PROVE-IT findings were strengthened by the
Aggressive Lipid-Lowering Initiation Abates New Cardiac
Events (ALLIANCE) study, which confirmed the hypothe-
sis of further benefits with aggressive cholesterol-lowering
[9]. In this trial, 2442 patients with coronary artery disease
were randomized to achieve LDL levels <80 mg/dl, receiv-
ing atorvastatin titrated at doses ≤  80 mg/day, or standard
therapy with the statins and doses chosen by the treating
physicians. Intensive lipid-lowering therapy demon-
strated a significant reduction in the primary end-point of
combined incidence of cardiac death, myocardial infarc-
tion, coronary revascularization and unstable angina
requiring hospitalization.
However, it should be pinpointed that lipid reduction,
decrease of markers of hemostasis and inflammation or
reduction in number of atherosclerotic plaques should be
viewed as surrogate end points of statins activity. The
extent to which these results can be extrapolated to clini-
cally relevant outcomes remains to be established [10]. It
is yet unclear whether all statins are equally effective in
preventing recurrent MI and death at a long-term follow-
up. Drugs in the same class are generally thought to be
therapeutically equivalent because of similar mechanisms
of action (the so-called "class effect" [11]). In this context,
however, statins differ in multiple characteristics, includ-
ing liver and renal metabolism, half-life, effects on several
serum lipid components, bioavailability and potency. In
addition, some are fungal derivatives, and others are syn-
thetic compounds. The percentage absorption of an oral
dose, amount of protein binding, degree of renal excre-
tion, hydrophilicity, and potency on a weight basis varies
among the individual agents [12,13]. Despite these differ-
ences, a just published Canadian retrospective cohort
study comparing atorvastatin, pravastatin, simvastatin,
lovastatin and fluvastatin in patients aged >65 years after
their first MI claims that all these statins are equally effec-
tive [10]. The study included above 18500 patients who
began statin treatment within 90 days after discharge, and
the primary end point was the combined outcome of
recurrent MI or death from any cause.
Trial-versus-trial comparisons
These comparisons present the hazard of being poten-
tially misleading because of fundamental "apples-to-
oranges" comparisons secondary to differences between
trials in patient populations, inclusion criteria, manage-
ment algorithms, and end-point definitions [14].
Although statins share common main actions, they may
have clinically important differences in terms of efficacy
and safety. In this context, it should be remembered that
as a result of 31 reported cases of fatal rhabdomyolysis,Cardiovascular Diabetology 2005, 4:8 http://www.cardiab.com/content/4/1/8
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cerivastatin was withdrawn from the market, underscor-
ing the risk of therapeutic interchangeability [15]. Modern
pharmacological decision-making and guidelines devel-
opment often rely on meta-analyses in order to handle the
vast amount of clinical information available from clini-
cal trials in cardiovascular medicine. Despite the estab-
lishment of standards for reporting meta-analyses, there
are also limitations that need to be acknowledged. Statis-
tical testing for heterogeneity of treatment effects across
drugs in a class is not a particularly sensitive analysis.
Thus, without access to original source data, reliably iden-
tifying adverse events can be very difficult [14].
An event illustrating this problem comes from New Zea-
land. After a government decision to replace simvastatin
with fluvastatin as the approved statin for reimbursement,
Thomas and Mann [16] investigated the effect of the
switch in 126 patients; the lipid concentrations went up in
115 (94%) of the patients after the switch to fluvastatin.
In addition, during the 6 months before the switch, there
were nine arterial thrombotic events compared with 27
during the same time after the switch (p < 0.05). This
study spells out the danger of allowing budgetary argu-
ments about class effects to influence drug selection.
Statins in diabetic patients
Part of the patients included in studies evaluating statins
are diabetics. Both the PROVE-IT [8] and the ALLIANCE
[9] trials were performed in populations comprising both
diabetic and nondiabetic patients, albeit the percentage of
diabetic patients was relatively small, averaging about
20% of the examinees.
Various trials demonstrated improved prognosis and
reduction of cardiovascular events in patients with diabe-
tes or impaired fasting glucose taking several statins [17-
20]. However, none of these was a head-to-head compar-
ison of two statins regarding their effectiveness in a dia-
betic population. The recently published study by Berne
and Siewert-Delle [21] addresses precisely this point.
Rosuvastatin was compared with atorvastatin in type 2
diabetes mellitus for the reduction of LDL-cholesterol.
They found that at 4 weeks, 65% of rosuvastatin patients
had reached their 2003 European LDL- cholesterol goal
(<2.5 mmol/L), compared with 33% of atorvastatin
patients (p < 0.0001). Both treatments were similarly well
tolerated with no unexpected safety concerns.
The mechanism behind these differences has not yet been
elucidated. A possible explanation is the dissimilarity in
their hepatic metabolization. Atorvastatin is a relatively
lipophilic compound; lipophilic statins are more suscep-
tible to metabolism by the cytochrome P450 system. On
the contrary, rosuvastatin is relatively hydrophilic and not
significantly metabolized by cytochrome P450 enzymes
[22]. Diabetes-induced abnormalities in P450 isoforms
were described in both experimental and clinical studies
[22-24]. This could explain the better compliance of dia-
betic patients to the latter drug.
Lipid-modifying strategy in metabolic syndrome 
and diabetes: beyond the LDL-cholesterol
Whereas statins remain the useful drug for patients who
need to achieve the LDL-cholesterol goal, other lipid-low-
ering compounds – fibrates – may represent the alterna-
tive intervention for subjects with atherogenic
dyslipidemia typical for metabolic syndrome and an LDL-
cholesterol already close to goal values. An atherogenic
dyslipidemia is characterized by elevated levels of triglyc-
erides, reduced levels of high-density lipoprotein choles-
terol and a preponderance of small dense LDL-cholesterol
particles.
The Adult Treatment Panel III guidelines suggest that
because elevated trigycerides are an independent CAD risk
factor, some trigyceride-rich lipoproteins, commonly
called remnant lipoproteins, must be atherogenic. A novel
method for the isolation and quantification of plasma
remnants was developed by Nakajima and Nakamura
[25]. Specific immunoaffinity-based gel is incubated with
plasma, which results in binding of high-density lipopro-
teins (HDL), LDL, and the majority of very low-density
lipoproteins (VLDL) particles to the gel. Unbound lipopro-
teins are quantified on the basis of their cholesterol con-
tent; this is termed the remnant-like particles cholesterol
(RLP-C) concentration. It is established that elevated
plasma RLP-C levels are associated with endothelial dys-
function, a marker for atherosclerotic disease. Patients
with established coronary heart disease present elevated
plasma levels of RLP-C. Elevated levels of plasma RLP-C
were predictive of future coronary events in patients with
CAD independently of other risk factors [26].
Extensive evidence from intervention trials has been pre-
sented to demonstrate that "old" statin treatment results
in reduced cardiovascular morbidity and mortality. By
contrast, statin treatment has not been associated consist-
ently with reduction in plasma RLP-C levels. In general,
however, it can be concluded that RLP-C lowering by stat-
ins depends on their ability to reduce triglyceride levels.
Therefore, among all currently clinically available statins
only atorvastatin and rosuvastatin have potential to
reduce RLP-C levels [27].
In addition, the concomitant use of fibrate and statin
seems to be attractive in patients whose LDL-cholesterol is
controlled by statin but whose HDL-cholesterol and/or
triglyceride levels are still inappropriate [28]. A combina-
tion statin/fibrate may be necessary to control all lipid
abnormalities in patients with metabolic syndrome andCardiovascular Diabetology 2005, 4:8 http://www.cardiab.com/content/4/1/8
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diabetes. Safety concerns about some fibrates such as
gemfibrozil may lead to exaggerate precautions regarding
fibrate administration and therefore diminish the use of
these agents. However, other fibrates- such as bezafibrate
and fenofibrate – appear to be safer and better tolerated
[29-32].
The combination of fibrate with statin which are not
mainly metabolized within the liver by the cytochrome
P450 system (like pravastatin or fluvastatin) may be even
less hazardous. We believe that a proper coadministration
of statins and fibrates in some cases, selected on basis of
their safety, could be more effective in achieving a com-
prehensive lipid control as compared with monotherapy.
An alternative sort of future combination may hypotheti-
cally be represented by ezetimibe and fibrate. Ezetimibe
represents the newest class of lipid-modifying agents. It
exerts its cholesterol-lowering effect by inhibiting the
absorption of both the dietary cholesterol and biliary cho-
lesterol at the brush border of the small intestine. Because
of its distinct mechanism of action, ezetimibe appears to
be most useful as part of combination therapy with other
lipid-modifying agents rather than as monotherapy.
Ezetimibe is approved currently for use alone or with stat-
ins, and initial study with fibrates are promising [32-34].
Desirability and feasibility
Prospective randomized parallel-group head-to-head
comparisons between different drugs were not performed
during the early stages of statins human use. The main rea-
son was the unwillingness of industry sponsors to take on
the risk of failing to show their drug is noninferior to
another agent in the same class [14]. Moreover, such a
study may potentially became a menacing 'boomerang" if
it demonstrates that the competitor's drug is preferable, as
it actually happened in the PROVE-IT trial [8]. While sta-
tistical techniques for estimating the comparative thera-
peutic efficacy of "competing" compounds using indirect
methods have been proposed, the soundness of these
adjusted indirect comparisons is limited, and depends on
the accuracy and similarity of the included trials [35].
Thus, it seems even needless to state that head-to-head
comparisons are preferable. It would be preferable that
every drug (and indeed every dose and every formulation
[36]) be evaluated in randomized comparative trials with
active comparators from the same class for their effects on
clinically important outcomes. This is not accomplished
since. Regretfully, in the real world things are more com-
plex.
Pharmaceutical companies spend millions of dollars to
convince consumers and doctors that their products are
superior to competitor brands; however, these companies
cannot be compelled to design and finance trials in which
a future monetary profit is dubious.
In addition, trials would require very large sample sizes
and long-term follow-up to detect significant differences
in myocardial infarction or death between two different
statins [35,36]. Moreover, the fact that new compounds,
like the presumably potent pitavastatin [37], are under
several phases of research and development represents an
additional drawback for performing the trials.
The assertion that there really does not appear to be much
difference across statins in terms of their effectiveness and
they appear to be similar one to another (in a study which
did not include rosuvastatin) [10] is seriously defied by
head-to-head comparisons performed so far [5-9,21,38].
Such assessments are of utmost importance, especially in
cases in which specific populations with a distinct lipid
profile and altered metabolic pathways [22-24], like dia-
betics, are studied.
Ideally, head-to-head trials regarding clinically importan-
toutcomes should be conducted for all drugs. Nonethe-
less, the desirability of performing such trials, which
epitomize modern evidence-based medicine, is frequently
superseded by the feasibility dictated by pragmatic and
economic circumstances. In absence of solid systematic
documentation of comparable health benefits and long-
term safety, both researchers and practicing physicians
should allude to the weight of scientific endorsement
behind the arguments and seek for the possible strengths
and weaknesses intrinsic to each specific study. In addi-
tion, surrogate end points, like LDL-cholesterol level,
allow conducting shorter and smaller trials with accepta-
ble level of credibility regarding clinical significance of the
new compound. A surrogate outcome will be reliable only
if there is a validated causal connection between change in
surrogate and change in the clinically important out-
comes (like morbidity and mortality), and if the surrogate
reflects most of the effects of treatment on a specific out-
come. The recent paper of Berne and Siewert-Delle [21]
denotes a good example for an accurate approach using a
relatively reliable (LDL-cholesterol level) surrogate end-
point. However, conclusions based on surrogate end-
points can not completely substitute head-to-head trials,
particularly in relation to the magnitude of potential ben-
efits in clinical practice.
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